USD10
TSHA azioni
Informazioni su Taysha Gene TherapiesTaysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
USD10
TSHA azioni
Informazioni su Taysha Gene TherapiesTaysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
Dati insufficienti
Capitalizzazione di mercato
1,21 Mld USD
PREZZO DI APERTURA
4,58 USD
MINIMO (1 anno)
1,05 USD
MASSIMO (1 anno)
6,02 USD
MINIMO (24H)
4,34 USD
MASSIMO (24 ore)
4,62 USD
VOLUME (24 ore)
5,53 Mln USD
2,36%
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | 4,58 USD | |
1 giorno | 4,40 USD | 0,00% |
1 settimana | 4,60 USD | |
1 mese | 4,77 USD | |
1 anno | 1,66 USD |